This paper calls for three important considerations:
- ‘First, the regulatory and research communities owe it to patients, families, and clinicians to quickly learn what treatments are effective...
- ‘Second, it is important to optimise treatments that already exist, including supportive critical care. As learned from the Ebola outbreak, mortality can be reduced through identifying best practices...
- ‘Third, and most important, it is critical to protect the integrity of and resulting public trust in the scientific and regulatory agencies and their advice and decisions. That trust will be needed once vaccines against COVID-19 become available and in future public health emergencies.’
Read here (JamaNetwork, April 16, 2020)